References
- Boultwood J, Pellagatti A, McKenzie AN, et al. Advances in the 5q- syndrome. Blood 2010;116:5803–5811.
- Oliva EN, Cuzzola M, Nobile F, et al. Changes in RPS14 expression levels during lenalidomide treatment in low- and intermediate- 1-risk myelodysplastic syndromes with chromosome 5q deletion. Eur J Haematol 2010;85:231–235.
- Giagounidis AA, Haase S, Heinsch M, et al: Lenalidomide in the context of complex karyotype or interrupted treatment: case reviews of del(5q) MDS patients with unexpected responses. Ann Hematol 2007;86:133–137.
- Breccia M, Cannella L, Latagliata R, et al. Unexpected erythroid and cytogenetic responses after discontinuation of a short course of lenalidomide as a result of severe skin rash in a patient with 5q syndrome. J Clin Oncol 2011;29:e402–e403.
- Messa E, Carturan S, Maffè C, et al. Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging. Haematologica 2010;95: 1308–1316.
- Messa E, Cilloni D, Messa F, et al. Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis. Acta Haematol 2008;120:70–74.
- Badawi MA, Vickars LM, Chase JM, et al. Red blood cell transfusion independence following the initiation of iron chelation therapy in myelodysplastic syndrome. Adv Hematol 2010;2010:164045.
- Gattermann N, Finelli C, Della Porta M, et al. Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes. Haematologica 2012;97: 1364–1371.
- Saigo K, Takenokuchi M, Hiramatsu Y, et al. Oxidative stress levels in myelodysplastic syndrome patients: their relationship to serum ferritin and haemoglobin values. J Int Med Res 2011;39: 1941–1945.
- Choi SO, Cho YS, Kim HL, et al. ROS mediate the hypoxic repression of the hepcidin gene by inhibiting C/EBPalpha and STAT-3. Biochem Biophys Res Commun 2007;356:312–317.
- Ghoti H, Fibach E, Merkel D, et al. Changes in parameters of oxidative stress and free iron biomarkers during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndromes. Haematologica 2010;95:1433–1434.